{"title":"Lung Cancer","description":null,"products":[{"product_id":"sugemalimab-cejemly","title":"Cejemly (Sugemalimab)","description":"\u003ch2\u003eAbout Cejemly® (Sugemalimab)\u003c\/h2\u003e\u003cp\u003eThe anti-PD-L1 monoclonal antibody sugemalimab was discovered by CStone using the OmniRat\u003csup\u003e®\u003c\/sup\u003e transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eThe NMPA of China has approved sugemalimab for four indications:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eIn combination with chemotherapy for first-line treatment of patients with metastatic squamous and non-squamous NSCLC.\u003c\/li\u003e\n\u003cli\u003eFor the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy.\u003c\/li\u003e\n\u003cli\u003eFor the treatment of patients with relapsed or refractory extranodal NK\/T-cell lymphoma.\u003c\/li\u003e\n\u003cli\u003eIn combination with fluorouracil and platinum-based chemotherapy for first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cspan class=\"LEwnzc Sqrs4e\"\u003eJuly 26, 2024 — \u003c\/span\u003eCStone Announces European Commission (EC) Approval of \u003cem\u003eCejemly\u003c\/em\u003e® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSugemalimab sold as brand name 择捷美® in china.\u003c\/li\u003e\n\u003cli\u003eSugemalimab sold as brand name Cejemly® in European Union.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eReference: 《\u003ca href=\"https:\/\/www.prnewswire.com\/news-releases\/cstone-announces-european-commission-approval-of-sugemalimab-cejemly-as-first-line-treatment-for-non-small-cell-lung-cancer-302207524.html\"\u003eCStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer\u003c\/a\u003e 》\u003c\/p\u003e","brand":"CStone Pharmaceuticals","offers":[{"title":"Default Title","offer_id":44797945970731,"sku":"RL29","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-07-262.png?v=1787022066"},{"product_id":"phoregoregorafenib","title":"ADADX (Adagrasib)","description":"\u003ch2\u003eAbout Adagrasib\u003c\/h2\u003e\r\nAdagrasib is a prescription medicine used in adults:\r\n\r\nalone to treat non-small cell lung cancer (NSCLC)\r\n\u003cul\u003e\r\n \t\u003cli\u003ethat has spread to other parts of the body or cannot be removed by surgery, and\u003c\/li\u003e\r\n \t\u003cli\u003ewhose tumor has an abnormal KRAS G12C gene, and\u003c\/li\u003e\r\n \t\u003cli\u003ewho have received at least one prior treatment.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nin combination with a medicine called cetuximab to treat colon or rectal cancer (CRC)\r\n\u003cul\u003e\r\n \t\u003cli\u003ethat has spread to other parts of the body or cannot be removed by surgery, and\u003c\/li\u003e\r\n \t\u003cli\u003ewhose tumor has an abnormal KRAS G12C gene, and\u003c\/li\u003e\r\n \t\u003cli\u003ewho have previously received certain chemotherapy medicines.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nYour healthcare provider will perform a test to make sure that Adagrasib is right for you.\r\n\r\nIt is not known if Adagrasib is safe and effective in children.\r\n\u003ch2\u003eNon–Small Cell Lung Cancer\u003c\/h2\u003e\r\nIndicated for KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer (NSCLC) in adults who have received ≥1 systemic treatment\r\n\r\n600 mg PO BID until disease progression or unacceptable toxicity\r\n\u003ch2\u003eColorectal Cancer\u003c\/h2\u003e\r\nIndicated in combination with cetuximab for KRAS G12C–mutated locally advanced or metastatic colorectal cancer (CRC) in adults who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy\r\n\r\n600 mg PO BID until disease progression or unacceptable toxicity\r\n\u003ch3\u003eIn a clinical trial, adagrasib was given with cetuximab\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e500 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV q2wks, or\u003c\/li\u003e\r\n \t\u003cli\u003e400 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV once followed by 250 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV once weekly\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\r\n\u003ch3\u003eDosage reductions for adverse reactions\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 400 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 600 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 600 mg qDay: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eNausea or vomiting\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4 despite providing supportive care (eg, antiemetic therapy)\u003c\/li\u003e\r\n \t\u003cli\u003eWithhold until recovery to Grade ≤1 or return to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eDiarrhea\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4 despite providing supportive care (eg, antidiarrheal therapy)\u003c\/li\u003e\r\n \t\u003cli\u003eWithhold until recovery to Grade ≤1 or return to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eQT interval prolongation\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eCorrected QT (QTc) absolute value \u0026gt;500 msec OR an increase \u0026gt;60 msec from baseline\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until QTc \u0026lt;481 msec or return to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePermanently discontinue\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTorsade de pointes\u003c\/li\u003e\r\n \t\u003cli\u003ePolymorphic ventricular tachycardia\u003c\/li\u003e\r\n \t\u003cli\u003eSigns or symptoms of serious or life-threatening arrhythmia\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHepatotoxicity\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 2 AST\/ALT: Decrease to next lower dose level\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eGrade 3 or 4 AST\/ALT\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovery to Grade ≤1 or return to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at next lower dose level\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003ePermanently discontinue\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAST\/ALT \u0026gt;3x ULN with total bilirubin \u0026gt;2x ULN in the absence of alternative causes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eInterstitial lung disease (ILD) or pneumonitis (any grade)\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eSuspected ILD\/pneumonitis: Withhold therapy\u003c\/li\u003e\r\n \t\u003cli\u003eConfirmed ILD\/pneumonitis: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eOther adverse reactions\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch4\u003eGrade 3 or 4\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold therapy until Grade ≤1 or return to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume therapy at next lower dose level\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eRenal impairment\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild to severe (CrCl 15 to \u0026lt;90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHepatic impairment\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild to severe (Child-Pugh A to C): No dosage adjustment necessary\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eDosing Considerations\u003c\/h2\u003e\r\n\u003ch3\u003eMonitoring Parameters\u003c\/h3\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMonitor ECGs and electrolytes before initiating, during treatment, and as clinically indicated in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, and in patients who are unable to avoid drugs known to prolong the QT interval\u003c\/li\u003e\r\n \t\u003cli\u003eMonitor AST, ALT, alkaline phosphatase, and total bilirubin before initiating and monthly for 3 months or as clinically indicated; perform more frequent testing in patients who develop transaminase elevations\u003c\/li\u003e\r\n \t\u003cli\u003eMonitor for new or worsening respiratory symptoms (eg, dyspnea, cough, fever) during treatment\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797946003499,"sku":"RL2720240715800","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-07-1479.jpg?v=1787022067"},{"product_id":"phoselp-40-selpercatinib","title":"OYSIENDX (Osimertinib)","description":"\u003cp\u003eOsimertinib  is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.\u003c\/p\u003e\u003cp\u003eThe most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.\u003c\/p\u003e\u003cp\u003eOsimertinib was approved for medical use in the United States in November 2015,and in the European Union in February 2016.\u003c\/p\u003e\u003cp\u003eOsimertinib is used to treat locally advanced or metastatic non-small-cell lung cancer (NSCLC), if the cancer cells are positive for the T790M mutation in the gene coding for EGFR or for activating EGFR mutations. The T790M mutation may be de novo or acquired following first-line treatment with other tyrosine kinase inhibitors (TKIs), such as gefitinib and afatinib.\u003c\/p\u003e\u003cp\u003eIn the US, EGFR exon 19 deletions, exon 21 L858R mutations or the T790M status of the patient prior to treatment with osimertinib must be detected by a federally approved companion diagnostic test.The Food and Drug Administration (FDA) has approved FoundationOne CDx as one available companion diagnostic test for this purpose. In Europe and elsewhere, activating EGFR mutations or T790M mutations may be determined by a validated test.\u003c\/p\u003e\u003cp\u003eIn people treated with osimertinib, resistance usually develops within approximately 10 months.Resistance mediated by an exon 20 C797S mutation accounts for the majority of resistance cases.\u003c\/p\u003e\u003cp\u003eIt can cause fetal harm, so should not be used in women who are pregnant, and women who take it should avoid becoming pregnant.\u003c\/p\u003e\u003cp\u003eCaution should be taken in people with a history of interstitial lung disease (ILD), as they were excluded from clinical trials, since the drug can cause severe ILD or pneumonitis. Caution should also be taken in people with a predisposition to long QT syndrome as the drug can provoke this.\u003c\/p\u003e\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003eOsimertinib is used to help prevent a certain type of non small-cell lung cancer (NSCLC) from returning after the tumor(s) has been removed by surgery in adults. It is also used as a first treatment for a certain type of NSCLC that has spread to other parts of the body in adults. Osimertinib is also used to treat certain types of NSCLC that has spread to other parts of the body in adults who could not be treated successfully with other similar chemotherapy medications. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors.\u003c\/p\u003e\u003cp\u003eHow should this medicine be used?\u003cbr\u003eOsimertinib comes as a tablet to take by mouth. It is usually taken with or without food once a day. The length of your treatment depends on how well this medication works for you, and the side effects that you experience. Take osimertinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take osimertinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\u003cp\u003eIf you cannot swallow the tablets, place the tablet into 4 tablespoons (2 oz [60 mL]) of water and stir until the tablet is in small pieces. Drink the mixture right away. Pour in another half a cup (4 oz [120 mL]) to a cup of water (8 oz [240 mL]) to the container you used, rinse, and drink to make sure you get the full dose of osimertinib. Do not use carbonated water or any other liquid to dissolve the osimertinib tablet. Do not crush the tablet or heat the mixture. If you have a nasogastric (NG) tube, your doctor or pharmacist will explain how to give this mixture through an NG tube.\u003c\/p\u003e\u003cp\u003eYour doctor may temporarily or permanently stop your treatment or decrease your dose of osimertinib depending on the side effects that you experience. Be sure to talk to your doctor about how you are feeling during your treatment. Do not stop taking osimertinib without talking to your doctor.\u003c\/p\u003e\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\u003cp\u003eOther uses for this medicine\u003cbr\u003eThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\u003cp\u003eWhat side effects can this medication cause?\u003cbr\u003eOsimertinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003cbr\u003ediarrhea\u003cbr\u003econstipation\u003cbr\u003erash\u003cbr\u003eitching\u003cbr\u003edry or cracking skin\u003cbr\u003eeczema\u003cbr\u003enausea\u003cbr\u003evomiting\u003cbr\u003eloss of appetite\u003cbr\u003eswelling or sores in the mouth\u003cbr\u003eback pain\u003cbr\u003enail changes including swelling, redness, pain, splitting, breaking, and separation or loss from nailbed.\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797946101803,"sku":"RL1220230820","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-08-2727.jpg?v=1787022068"},{"product_id":"photalaz-1-talazoparib","title":"ハイイータン (Glumetinib)","description":"\u003ch2\u003eAbout Glumetinib or \u003cstrong\u003eGumarontinib\u003c\/strong\u003e\n\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eGlumetinib (SCC244) \u003c\/strong\u003ealso named \u003cstrong\u003eGumarontinib，\u003c\/strong\u003e is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor.Glumetinib has excellent pharmacokinetic characteristics with long half-life and high steady-state trough concentration in human body, which is conducive to the continuous inhibition of the target.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGlumetinib sold as brand name 海益坦® in china.\u003c\/li\u003e\n\u003cli\u003eGumarontinib sold as brand name ハイイータン® in Japan.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eApproval\u003c\/h2\u003e\u003cp\u003eIn June 2024, the MET inhibitor Glumetinib tablets were approved for marketing by the Ministry of Health, Labor and Welfare of Japan for the treatment of locally advanced or metastatic non-small cell lung cancer with MET exon 14 mutations.\u003c\/p\u003e\u003cp style=\"font-weight: 400\"\u003e\u003ca href=\"https:\/\/kk.haihepharma.com\/news\/news_2024062401.html\"\u003e《MET阻害剤「ハイイータン\u003csub\u003e® \u003c\/sub\u003e錠50 mg」\u003cem\u003eMET\u003c\/em\u003e遺伝子エクソン14スキッピング変異陽性の切除不能な進行・再発の非小細胞肺癌に対する製造販売承認を取得》\u003c\/a\u003e\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.haihepharma.com\/en\/news\/details\/423\"\u003e《An innovative drug Gumarontinib (MET inhibitor) discovered and developed by Haihe Biopharma has been successfully approved in Japan》\u003c\/a\u003e\u003c\/p\u003e\u003ch2\u003eDosage and administration\u003c\/h2\u003e\u003cp\u003eThe recommended dose of Glumetinib is 80 mg, taken orally once a day until disease progression or intolerable toxicity occurs.\u003cbr\u003eGlumetinib should be taken on an empty stomach. Take Glumetinib at approximately the same time every day, swallow the whole tablet with water, do not crush or chew. If the patient misses a dose of Glumetinib and the next dose is more than 12 hours away, the patient should take Glumetinib.\u003c\/p\u003e\u003ch3\u003eDose adjustment\u003c\/h3\u003e\u003cp\u003eIf adverse events occur during the use of Glumetinib, the drug can be temporarily interrupted, the dose can be reduced, or the treatment with Glumetinib can be stopped according to the specific situation. If a reduction in dose is required, the dose can be reduced to 40 mg, once a day.\u003c\/p\u003e","brand":"Haihe pharma, China","offers":[{"title":"Default Title","offer_id":44797946331179,"sku":"RL2720240718","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-07-0321.jpg?v=1787022071"},{"product_id":"briganix-brigatinib-2","title":"Larotreni (Larotrectinib)","description":"Larotrectinib is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change. You might have larotrectinib for a solid cancer if: your cancer is locally advanced or advanced (metastatic) surgery to remove the cancer could cause severe health problems.\r\n\u003ch3\u003eSolid Tumors\u003c\/h3\u003e\r\nIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\r\n\r\n100 mg PO BID\r\n\r\nContinue until disease progression or until unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eBody Surface Area (BSA) ≥1 m2\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946396715,"sku":"RL1420230901296990","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1444.png?v=1787022074"},{"product_id":"giefoni-gefitinib-250mg","title":"Giefoni (Gefitinib)","description":"\u003cstrong\u003e[Indications]\u003c\/strong\u003e\r\n\r\nGiefoni is a tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) where epidermal growth factor receptor (EGFR) exon 19 is absent or exon 21 (L858R) replaces the mutant type.\r\n\r\nMedication limitations: the safety and efficacy of Giefoni for EGFR mutations other than exon 19 deletion or exon 21 (L858R) replacement mutations have not been determined\r\n\r\n\u003cstrong\u003e[\u003c\/strong\u003e\u003cstrong\u003eHow to take the drug]\u003c\/strong\u003e\r\n\r\n1. Therapy period\r\n\r\nRecommended dosage: 250mg, taken orally, once daily; Not with food or with food.\r\n\r\n2. Dosage form specification:\r\n\u003cul\u003e\r\n \t\u003cli\u003eTablet, 250mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n3. Contraindications\r\n\r\nNone\r\n\r\n\u003cstrong\u003e[Warnings and precautions]\u003c\/strong\u003e\r\n\r\n● \u003cstrong\u003eInterstitial lung disease (ILD) :\u003c\/strong\u003e there may be ILD during giffornia.  If the ILD is confirmed, the medication is terminated.\r\n\r\n● \u003cstrong\u003eH\u003c\/strong\u003e\u003cstrong\u003eepatotoxicity: \u003c\/strong\u003eregular liver function testing. The presence of elevated ALT and\/or AST at level 2 or higher requires a drug break. Discontinue medication if severe liver damage occurs\r\n\r\n●\u003cstrong\u003eGastrointestinal perforation\u003c\/strong\u003e: discontinue medication if gastrointestinal perforation occurs.\r\n\r\n●\u003cstrong\u003eDiarrhea\u003c\/strong\u003e: medication suspension is required for diarrhea of grade 3 or higher.\r\n\r\n●\u003cstrong\u003eEye diseases include keratitis\u003c\/strong\u003e: severe or worsening eye diseases include signs and symptoms of keratitis requiring medication discontinuation, and discontinuation of medication for prolonged ulcerative keratitis.\r\n\r\n●\u003cstrong\u003eCowhide and exfoliating skin diseases\u003c\/strong\u003e: drug suspension is required for skin reactions or peeling at grade 3 or higher.\r\n\r\n●\u003cstrong\u003eE\u003c\/strong\u003e\u003cstrong\u003embryonic toxicity\u003c\/strong\u003e: may cause fetal damage. Effective contraceptive measures are recommended to avoid potential fetal risks.\r\n\r\n\u003cstrong\u003e[Side-effect]\u003c\/strong\u003e\r\n\r\nMore than 20 percent of the most common side effects in the placebo group were skin reactions and diarrhea.\r\n\r\n\u003cstrong\u003e[How to store the drug]\u003c\/strong\u003e\r\n\r\nKeep this medicine at dark, cool and dry place.","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946789931,"sku":"RL1420230901102","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655977414-14b07825315253a.png?v=1787022082"},{"product_id":"osiem","title":"Osiem (Osimertinib)","description":"\u003cstrong\u003e[Indications]\u003c\/strong\u003e\r\n\r\nIt is used for the treatment of advanced patients with metastatic non-small cell lung cancer (NSCLC) with positive EGFRT790M mutation in or after treatment with epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI).\r\n\r\n\u003cstrong\u003e[\u003c\/strong\u003e\u003cstrong\u003eHow to take the drug]\u003c\/strong\u003e\r\n\r\n1. Therapy period\r\n\r\n● Before using this product, please confirm the presence of EGFRT790M mutation in the patient's tumor specimens.\r\n\r\n● The recommended dose is 80mg\/ tablet once a day until the disease progresses or the patient cannot tolerate it.\r\n\r\n● Can be taken with or without food.\r\n\r\n● If you miss this dose, you don't need to take it again, just take it at the prescribed time next time.\r\n\r\n● If the patient has difficulty swallowing, dissolve the product in about 50ml warm boiled water (do not use carbonated drinks) and rinse with clean water at last. Do not crush, heat or ultrasonic crush during dissolution.\r\n\r\n2. Dosage form specification\r\n\r\n● Tablet, 80mg, 40mg.\r\n\r\n3. Contraindications\r\n\r\nNone.\r\n\r\n\u003cstrong\u003e[Warnings and precautions]\u003c\/strong\u003e\r\n\r\n● Interstitial lung disease\/pneumonia if the patient develops severe respiratory symptoms during treatment, the product should be suspended and the cause should be investigated promptly. If proved to be interstitial lung disease, the drug is permanently discontinued..\r\n\r\n● For those with congenital long QTc syndrome, congestive heart failure, electrolyte disorders, and those who are taking medications that can cause the extension of QTc, regular ecg monitoring and electrolyte chemistry should be performed.  In the event of prolonged QTc intervals and the appearance of life-threatening arrhythmia, the drug should be permanently discontinued.\r\n\r\n● Cardiomyopathy should be evaluated with an echocardiography or MUGA scan every three months prior to administration and during treatment.  If the ratio of LVEF to pre-treatment is reduced by 10% and the value is less than 50%, the drug should be suspended. For symptomatic congestive heart failure or persistent asymptomatic left ventricular dysfunction that does not resolve within four weeks, drug withdrawal is permanent.\r\n\r\n● The embryo-fetal toxicity is based on the data of animal experiments and the drug mechanism of this product, which can cause serious harm to the pregnant fetus. Women are advised to use effective contraception while taking the medication and within six weeks of stopping.   Men are advised to use effective contraception during treatment and up to four months after withdrawal.\r\n\r\n\u003cstrong\u003e[Side-effect]\u003c\/strong\u003e\r\n\r\nCommon side effect: diarrhea, nausea, loss of appetite, constipation, rash, dry skin, toxic nails, etc.\r\n\r\n\u003cstrong\u003e[How to store the drug]\u003c\/strong\u003e\r\n\r\nKeep this medicine at room temperature (25℃).","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946888235,"sku":"RL1420230901102","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Osiem.jpg?v=1787906987"},{"product_id":"aentrekentrectinib-100mg","title":"Aentrek 100 (entrectinib)","description":"\u003cdiv class=\"collapse-more\"\u003e\r\n\u003ch3\u003e\u003cspan id=\"Non-small_Cell_Lung_Cancer\"\u003eNon-small Cell Lung Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003c\/div\u003e\r\nIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are ROS1-positive\r\n\r\n600 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Neurotrophic_Tyrosine_Receptor_Kinase_Gene_Fusion_Solid_Tumors\"\u003eNeurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumors\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and progressed following treatment or have no satisfactory alternative therapy\r\n\r\n600 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 400 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 200 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003ePermanently discontinue if toxicities persist or recur following 2 dose reductions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Congestive_heart_failure\"\u003eCongestive heart failure\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 2 or 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Central_nervous_system_effects\"\u003eCentral nervous system effects\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIntolerable Grade 2: Withhold until recovered to Grade ≤1; resume at reduced dose, as clinically appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatoxicity\"\u003eHepatoxicity\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduced dose;\u003c\/li\u003e\r\n \t\u003cli\u003eIf resolution occurs within 4 weeks, resume at same dose\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reaction persists after 4 weeks, permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eFor recurrent Grade 3 events that resolve within 4 weeks, resume at a reduced dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Grade_4\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduce dose;\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reaction does not resolve within 4 weeks or Grade 4 events recurs, permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Elevated_ALT_or_AST\"\u003eElevated ALT or AST\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eALT or AST \u0026gt;3x ULN with concurrent total bilirubin \u0026gt;1.5x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hyperuricemia\"\u003eHyperuricemia\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eSymptomatic or Grade 4: Initiate urate-lowering therapy; withhold until improvement of signs or symptoms; resume at same or reduced dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"QTc_prolongation\"\u003eQTc prolongation\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"QTc_500_ms\"\u003eQTc \u0026gt;500 ms\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until QTc interval recovers to baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at same dose if causes of QT prolongation are identified and corrected\u003c\/li\u003e\r\n \t\u003cli\u003eResume at reduced dose if other causes of QT prolongation are not identified\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Life-threatening_arrhythmia\"\u003eLife-threatening arrhythmia\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eTorsade de pointes; polymorphic ventricular tachycardia; signs\/symptoms of serious arrhythmia: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Vision_disorders\"\u003eVision disorders\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade ≥2: Withhold until improvement or stabilization; resume at same dose or reduced dose, as clinically appropriate\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Anemia_or_neutropenia\"\u003eAnemia or neutropenia\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until recovery to Grade≤2; resume at same or reduced dose, as clinically appropriate\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Other_clinically_relevant_adverse_reactions\"\u003eOther clinically relevant adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"Grade_3_or_4\"\u003eGrade 3 or 4\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until adverse reaction resolves to Grade 1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eResume at same or reduced dose if resolved within 4 weeks\u003c\/li\u003e\r\n \t\u003cli\u003ePermanently discontinue if adverse reaction does not resolve within 4 weeks or Grade 4 events recurs\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Coadministration_of_moderate_and_strong_CYP3A_inhibitors\"\u003eCoadministration of moderate and strong CYP3A inhibitors\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAvoid coadministration\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e\u003cspan id=\"If_coadministration_is_unavoidable_reduce_entrectinib_dose_as_follows\"\u003eIf coadministration is unavoidable, reduce entrectinib dose as follows:\u003c\/span\u003e\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eModerate CYP3A Inhibitors: 200 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eStrong CYP3A Inhibitors: 100 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eAfter discontinuation of strong or moderate CYP3A inhibitor for 3-5 elimination half-lives, resume entrectinib dose taken prior to initiating the CYP3A inhibitor\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl 30 to \u0026lt;90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not studied\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild (total bilirubin ≤1.5x ULN): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eModerate-to-severe (total bilirubin \u0026gt;1.5x ULN): Not studied; consider risk-benefit profile prior to determining whether to administer therapy to patients with moderate to severe hepatic impairment; monitor for adverse reactions in patients with hepatic impairment more frequently; these patients may be at increased risk for adverse reactions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Patient_selection\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eNSCLC: Presence of ROS1 rearrangement\u003c\/li\u003e\r\n \t\u003cli\u003eLocally advanced or metastatic solid tumors: Presence of a NTRK gene fusion\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947019307,"sku":"RL1420230901535","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663296906-991924d4ac643fa.jpg?v=1787022083"},{"product_id":"aentrek","title":"Aentrek 200 (Entrectinib)","description":"\u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. It is also used to treat certain types of solid tumors in adults and children 12 years of age and older that cannot be treated by surgery or that has spread to other parts of the body and that worsened after treatment with other chemotherapy medications. \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.\r\n\r\n\u003cstrong\u003e\u003cu\u003eUsage\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib)at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.\r\n\r\nTake \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\r\n\r\nSwallow the capsules whole; do not open, chew, or crush them.\r\n\r\nIf you vomit immediately after you take \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), take another dose as soon as possible.\r\n\r\nAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\r\n\r\n\u003cstrong\u003e\u003cu\u003eOther uses for this medicine\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\r\n\r\n\u003cstrong\u003e\u003cu\u003eSpecial precautions should follow\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eBefore taking Aentrek(entrectinib)\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003etell your doctor and pharmacist if you are allergic to \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), any other medications, or any of the ingredients in \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) capsules. Ask your pharmacist for a list of the ingredients.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the following: aprepitant (Emend), certain antifungal medications such as fluconazole (Diflucan), itraconazole (Omel, Sporanox), or ketoconazole; certain medications for arrhythmias such as amiodarone (Nexterone, Pacerone), procainamide, quinidine (in Nuedexta), and sotalol (Betapace, Sorine, Sotylize); azithromycin (Zithromax); clarithromycin (Biaxin, in Prevpac); diltiazem (Cardizem, Tiazac, others); erythromycin (E.E.S., Erythrocin, others); enzalutamide (Xtandi); certain HIV medications such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, others), or saquinavir (Invirase); lithium (Lithobid); modafinil (Provigil); nefazodone; oxcarbazepine (Trileptal); phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus, Duetact, Oseni); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifater); oral steroids such as dexamethasone, methylprednisolone (Medrol), and prednisone (Rayos); and verapamil (Calan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor what herbal products you are taking.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor if you have or have ever had a nervous system condition, a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), a slow or irregular heartbeat, a heart attack, heart failure, or heart or liver disease.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for at least 5 weeks after your final dose. If you are a male, you and your partner should use birth control during your treatment with \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib), call your doctor immediately. Entrectinib may harm the fetus.\u003c\/li\u003e\r\n \t\u003cli\u003etell your doctor if you are breastfeeding. You should not breastfeed while you are taking \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) and for 7 days after the final dose.\u003c\/li\u003e\r\n \t\u003cli\u003eyou should know that \u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib)may make cause dizziness or confusion. Do not drive a car or operate machinery until you know how this medication affects you.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003e\u003cu\u003eSpecial dietary instructions should I follow\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\nDo not eat grapefruit or drink grapefruit juice while taking this medication.\r\n\r\n\u003cstrong\u003eMissed or forget a dose\u003c\/strong\u003e\r\n\r\nIf you miss a dose by less than 12 hours, take the missed dose as soon as you remember it and then take the next dose at the scheduled time. However, if you miss a dose by more than 12 hours, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.\r\n\r\n\u003cstrong\u003e\u003cu\u003eSide effects can this medication cause?\u003c\/u\u003e\u003c\/strong\u003e\r\n\r\n\u003cstrong\u003eAentrek(entrectinib) may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003etiredness\u003c\/li\u003e\r\n \t\u003cli\u003econstipation\u003c\/li\u003e\r\n \t\u003cli\u003ediarrhea\u003c\/li\u003e\r\n \t\u003cli\u003etaste changes\u003c\/li\u003e\r\n \t\u003cli\u003eheadache\u003c\/li\u003e\r\n \t\u003cli\u003ecough, fever, or other signs of infection\u003c\/li\u003e\r\n \t\u003cli\u003emuscle or joint pain\u003c\/li\u003e\r\n \t\u003cli\u003eback pain\u003c\/li\u003e\r\n \t\u003cli\u003eweight changes\u003c\/li\u003e\r\n \t\u003cli\u003erash\u003c\/li\u003e\r\n \t\u003cli\u003edifficulty falling or staying asleep\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eSome side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003edifficulty with learning, memory, attention, or problem solving\u003c\/li\u003e\r\n \t\u003cli\u003emood changes such as anxiety, depression, confusion, or agitation\u003c\/li\u003e\r\n \t\u003cli\u003ebone pain or difficulty moving\u003c\/li\u003e\r\n \t\u003cli\u003evision problems or changes in vision\u003c\/li\u003e\r\n \t\u003cli\u003ejoint pain, stiffness, redness, or swelling\u003c\/li\u003e\r\n \t\u003cli\u003epain in upper right part of the stomach, yellowing of skin or eyes, loss of appetite, or bleeding or bruising easily\u003c\/li\u003e\r\n \t\u003cli\u003eshortness of breath; difficulty breathing when lying down; or swelling of the arms, legs, hands, or feet\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAentrek\u003c\/strong\u003e(entrectinib) may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947052075,"sku":"RL14202309011545","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-08-2413.jpg?v=1787022085"},{"product_id":"cerini-certinib-150mg","title":"Cerini (Ceritinib)","description":"\u003cb\u003eCeritinib\u003c\/b\u003e is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC).\u003csup id=\"cite_ref-Medscape_4-0\" class=\"reference\"\u003e\u003c\/sup\u003e\r\n\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test\r\n\r\n450 mg PO qDay with food\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\r\nAlso see administration\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDose reduction increments\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eStarting dose: 450 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eFirst dose reduction: 300 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 150 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 150 mg\/day: Discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947314219,"sku":"RL1420230901650","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663217182-e45ee7ce7e88149.png?v=1787022091"},{"product_id":"phosotor-sotorasib-2","title":"Sotoraib (Sotorasib)","description":"\u003cp\u003eSotorasib is an anti-cancer medication used to treat non-small-cell lung cancer (NSCLC).It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.\u003c\/p\u003e\n\n\u003cp\u003eSotorasib is an inhibitor of the RAS GTPase family.\u003c\/p\u003e\n\n\u003cp\u003eSotorasib is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers.KRAS G12C mutations occur in about 13% of patients with non-small cell lung cancers.Sotorasib was approved for medical use in the United States in May 2021.\u003c\/p\u003e\n\n\u003cp\u003eMedical uses\u003cbr\u003e\nSotorasib is indicated for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nSotorasib is used to treat a certain type of lung cancer (non-small cell lung cancer; NSCLC) that has spread to other parts of the body or cannot be removed by surgery in adults who have received at least one other treatment. Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nSotorasib comes as a tablet to take by mouth. It is usually taken once daily with or without food. Take sotorasib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take sotorasib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the tablets whole; do not split, chew, or crush them.\u003c\/p\u003e\n\n\u003cp\u003eIf you cannot swallow the tablets whole, place the tablets in a glass of 4 ounces (120 mL) of non-carbonated, room temperature water. Do not use any other liquids other than water. Stir until the tablets are in small pieces. Do not crush the tablets; they will not completely dissolve. Drink the mixture right away or within 2 hours of preparing. Do not chew pieces of the tablet. Rinse the glass with an additional 4 ounces (120 mL) of water and drink to make sure that you have taken the full dose. If you do not drink the mixture right away, stir the mixture again before drinking.\u003c\/p\u003e\n\n\u003cp\u003eIf you vomit after taking sotorasib, do not take another dose. Continue your regular dosing schedule the next day.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may temporarily or permanently stop your treatment or adjust your dose of sotorasib depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take sotorasib even if you feel well. Do not stop taking sotorasib without talking to your doctor.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947346987,"sku":"RL14202309011090","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-08-2052.png?v=1787022092"},{"product_id":"cerini-certinib-150mg-2","title":"Alynni (Alectinib)","description":"Alectinib is a type of cancer growth blocker called a tyrosine kinase inhibitor. It works by blocking certain chemical messengers that tell cells to grow. This stops or slows down the cancer.\r\n\u003ch3\u003eApproval in Japan\u003c\/h3\u003e\r\n\u003cp class=\"heading-title\"\u003eAlectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma .\u003c\/p\u003e\r\n\r\n\u003ch3\u003eNon-small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test\r\n\r\n600 mg PO BID until disease progression or unacceptable toxicity\r\n\r\nSee Administration\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDose reduction schedule\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eStarting dose: 600 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eFirst dose reduction: 450 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 300 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eDiscontinue if patients are unable to tolerate 300 mg PO BID\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947379755,"sku":"RL1420230901745","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655105951-634aa7e02ad1412.jpg?v=1787022092"},{"product_id":"lorlatini-25-lorlatinib-2","title":"Lorlatini 25 (Lorlatinib)","description":"\u003cp\u003eLorlatinib, sold under the brand name Pholorla100,Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.\u003c\/p\u003e\n\n\u003cp\u003eMedical uses\u003cbr\u003e\nLorlatinib is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).It is the only ALK inhibitor with meaning activity against ALK G1202R mutation in lung cancer.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nLorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. Lorlatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nLorlatinib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Take lorlatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take lorlatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eIf you vomit after taking the medication, do not take another dose. Continue your regular dosing schedule.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the tablets whole; do not split, chew, or crush them. Do not take tablets that are already broken or cracked.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may decrease your dose or temporarily or permanently stop your treatment depending on if you experience any side effects. Be sure to tell your doctor how you are feeling during your treatment with lorlatinib.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\n\n\u003cp\u003eWhat side effects can this medication cause?\u003cbr\u003e\nLorlatinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003cbr\u003e\nweight gain\u003cbr\u003e\nmuscle, joint, or back pain\u003cbr\u003e\ndiarrhea\u003cbr\u003e\nconstipation\u003cbr\u003e\nnausea\u003cbr\u003e\nvomiting\u003cbr\u003e\ntiredness\u003cbr\u003e\nheadache\u003cbr\u003e\nvision changes\u003cbr\u003e\nrash or itching.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947871275,"sku":"RL1420230901255","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663301348-120a01162d06a58.jpg?v=1787022102"},{"product_id":"lorlatini-100-lorlatinib","title":"Lorlatini 100 (Lorlatinib)","description":"\u003cp\u003eLorlatinib, sold under the brand name Lorlatini,Lorbrena among others in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.\u003c\/p\u003e\n\n\u003cp\u003eMedical uses\u003cbr\u003e\nLorlatinib is approved in the US and in Europe for the second- or third-line treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).It is the only ALK inhibitor with meaning activity against ALK G1202R mutation in lung cancer.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nLorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. Lorlatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nLorlatinib comes as a tablet to take by mouth. It is usually taken with or without food once daily. Take lorlatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take lorlatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eIf you vomit after taking the medication, do not take another dose. Continue your regular dosing schedule.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the tablets whole; do not split, chew, or crush them. Do not take tablets that are already broken or cracked.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may decrease your dose or temporarily or permanently stop your treatment depending on if you experience any side effects. Be sure to tell your doctor how you are feeling during your treatment with lorlatinib.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e\n\n\u003cp\u003eWhat side effects can this medication cause?\u003cbr\u003e\nLorlatinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\u003cbr\u003e\nweight gain\u003cbr\u003e\nmuscle, joint, or back pain\u003cbr\u003e\ndiarrhea\u003cbr\u003e\nconstipation\u003cbr\u003e\nnausea\u003cbr\u003e\nvomiting\u003cbr\u003e\ntiredness\u003cbr\u003e\nheadache\u003cbr\u003e\nvision changes\u003cbr\u003e\nrash or itching.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947904043,"sku":"RL1420230901721","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663301527-4dd4dd4530fd3ca.jpg?v=1787022103"},{"product_id":"ventok-10-venetoclax","title":"MOBODX (Mobocertinib)","description":"Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.\r\n\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for locally advanced or metastatic non–small cell lung cancer (NSCLC) in adults with epidermal growth factor receptor (EGFR) exon 20 insertion mutations and whose disease has progressed on or after platinum-based chemotherapy\r\n\r\n160 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDose reductions for adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 120 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 80 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eBlack Box Warnings\u003c\/h3\u003e\r\n\u003ch4\u003eQTc prolongation and torsades de pointes\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eLife-threatening heart rate–corrected QTc prolongation, including torsades de pointes, may occur\u003c\/li\u003e\r\n \t\u003cli\u003eMonitor QTc and electrolytes periodically during treatment\u003c\/li\u003e\r\n \t\u003cli\u003eIncrease monitoring frequency in patients with risk factors for QTc prolongation (eg, congenital long QT syndrome, heart disease, electrolyte abnormalities)\u003c\/li\u003e\r\n \t\u003cli\u003eAvoid coadministration with drugs that may further prolong the QTc interval (eg, drugs known to prolong QTc interval, strong or moderate CYP3A inhibitors)\u003c\/li\u003e\r\n \t\u003cli\u003eWithhold, reduce dose, or permanently discontinue treatment based on the severity of QTc prolongation\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797948100651,"sku":"RL11202300803600","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-08-0551.jpg?v=1787022107"},{"product_id":"lorbrena-lorlatinnib-25mg","title":"LORLADX 25 (Lorlatinib)","description":"Lorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. Lorlatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003e\u003cspan id=\"Non-small_Cell_Lung_Cancer\"\u003eNon-small Cell Lung Cancer\u003c\/span\u003e\u003c\/h3\u003e\r\nIndicated for metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test\r\n\r\n100 mg PO qDay with or without food\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\r\n\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 75 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 50 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 50 mg qDay: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797948330027,"sku":"RL1020230315300","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-06-0822.jpg?v=1787022113"},{"product_id":"generic-regorafenib","title":"Teponi (Tepotinib)","description":"Tepotinib is a kinase inhibitor directed against MET, including variants with exon 14 skipping - it inhibits MET phosphorylation and subsequent downstream signaling pathways in order to inhibit tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells.\r\n\u003ch3\u003eNon–Small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for metastatic non–small cell lung cancer (NSCLC) in adults harboring mesenchymal-epithelial transition (MET) exon 14 (ex14) skipping alterations\r\n\r\n450 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\nRecommended dose reduction to manage adverse reactions: 225 mg PO qDay\r\n\r\nPermanently discontinue if unable to tolerate 225 mg PO qDay\r\n\u003ch4\u003eInterstitial lung disease (ILD)\/ pneumonitis\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eSuspected ILD (any grade): Withhold\u003c\/li\u003e\r\n \t\u003cli\u003eConfirmed ILD: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eIncreased AST\/ALT and\/or total bilirubin\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eGrade 3 increased AST\/ALT without increased total bilirubin\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovery to baseline ALT\/AST\u003c\/li\u003e\r\n \t\u003cli\u003eIf recovered to baseline ≤7 days, resume at same dose; otherwise, resume at a reduced dose\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eGrade 3 increased total bilirubin without concurrent increased AST\/ALT\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eWithhold until recovery to baseline total bilirubin\u003c\/li\u003e\r\n \t\u003cli\u003eIf recovered to baseline ≤7 days, resume at reduced dose; otherwise, permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003ePermanently discontinue\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 4 increased ALT\/AST without increased total bilirubin\u003c\/li\u003e\r\n \t\u003cli\u003eALT\/AST \u0026gt;3x ULN with total bilirubin \u0026gt;2x ULN without cholestasis or hemolysis\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 increased total bilirubin without concurrent increased AST\/ALT\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 2: Maintain dose; if intolerable, consider withholding until resolved, then resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until resolved, then resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRenal impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Recommended dose not established\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (Child-Pugh Class A or B): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003eSevere (Child-Pugh Class C): Pharmacokinetics and safety not studied\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948657707,"sku":"RL14202309011545","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-08-2846.jpg?v=1787022120"},{"product_id":"generic-crizotinib","title":"Kayzoni (Crizotinib)","description":"\u003cp\u003eCrizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.\u003c\/p\u003e\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)- or ROS1-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eInflammatory Myofibroblastic tumors\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT) in adults who are ALK-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 250 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 250 mg PO qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948756011,"sku":"RL1020230315560","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1046.jpg?v=1787022123"},{"product_id":"generic-brigatinib","title":"Beigani (Brigatinib)","description":"Brigatinib is a targeted cancer drug treatment for non small cell lung cancer (NSCLC). It is also known as Alunbrig. It is a treatment for a type of lung cancer called non small cell lung cancer (NSCLC) that has spread to other parts of the body (advanced or metastatic NSCLC).\r\n\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)\r\n\r\n90 mg PO qDay for the first 7 days; if 90 mg\/day tolerated, increase to 180 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\nIf treatment is interrupted for ≥14 days for reasons other than adverse reactions, resume at 90 mg qDay for 7 days before increasing to previously tolerated dose\r\n\u003ch4\u003eDose reductions\u003c\/h4\u003e\r\nOnce discontinued, do not subsequently increase dose\r\n\r\nPermanently discontinue if unable to tolerate 60 mg\/day\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e90 mg\/day dose\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst reduction: 60 mg qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003e180 mg\/day dose\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst reduction: 120 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond reduction: 90 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird reduction: 60 mg qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948919851,"sku":"RL142023090183238","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1125.jpg?v=1787022124"},{"product_id":"generic-lorlatinib","title":"LORLADX 100 (Lorlatinib)","description":"Lorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. Lorlatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003eNon-small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test\r\n\r\n100 mg PO qDay with or without food\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 75 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 50 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 50 mg qDay: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797948952619,"sku":"RL1020230315600","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-05-2636.jpg?v=1787022125"},{"product_id":"generic-capmatinib","title":"CAMPMADX (Capmatinib)","description":"Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.\r\n\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping\r\n\r\n400 mg PO BID\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\nDose reductions for adverse reactions\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Restart at 300 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Restart at 200 mg PO BID\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 200 mg PO BID: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797948985387,"sku":"RL1020230315800","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-05-2640.jpg?v=1787022127"},{"product_id":"generic-sotorasib-sotrdx","title":"SOTOLDX (Sotorasib)","description":"Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\r\nIndicated for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received ≥1 prior systemic therapy\r\n\r\n960 mg PO qDay\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDosage reduction levels for adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst dose reduction: 480 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond dose reduction: 240 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 240 mg qDay: Discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949804587,"sku":"RL10202303151200","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-06-1918.jpg?v=1787022136"},{"product_id":"generic-larotrectinib-lucilaro","title":"PRASEDX (Pralsetinib)","description":"\u003ch2\u003eAbout  Pralsetinib\u003c\/h2\u003e\u003cp\u003ePralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.\u003c\/p\u003e\u003cp\u003ePralsetinib is a medication approved\u003csup id=\"cite_ref-10\" class=\"reference\"\u003e\u003c\/sup\u003e for RET mutation-positive medullary thyroid cancer (MTC)  and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy.\u003c\/p\u003e\u003cp\u003ePralsetinib is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) .\u003csup id=\"cite_ref-FDA_pralsetinib_12-4\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003eNon-Small Cell Lung Cancer\u003c\/h2\u003e\u003cp\u003eIndicated for metastatic rearranged during transfection (RET) gene-positive non-small cell lung cancer (NSCLC)\u003c\/p\u003e\u003cp\u003e400 mg PO qDay on an empty stomach\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eMedullary Thyroid Cancer\u003c\/h2\u003e\u003cp\u003eIndication was withdrawn in the U.S. by manufacturer on July 10, 2023\u003c\/p\u003e\u003cp\u003eThe decision was made to remove the indication after the confirmatory trial could not fulfill the postmarketing requirement\u003c\/p\u003e\u003ch2\u003eThyroid Cancer\u003c\/h2\u003e\u003cp\u003eIndicated for advanced or metastatic RET-fusion positive thyroid cancer in adults who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate)\u003c\/p\u003e\u003cp\u003e400 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\u003ch3\u003eDosage modifications for adverse reactions\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 300 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eThird dose reduction: 100 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eInterstitial lung disease (ILD)\/pneumonitis\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 1 or 2: Withhold until resolution; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 or recurrent ILD\/pneumonitis: Permanent discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHypertension\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold for persistent Grade 3 hypertension despite optimal antihypertensive therapy; resume at reduced dose once hypertension controlled\u003c\/li\u003e\n\u003cli\u003eGrade 4: Discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHepatoxicity\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold and monitor AST\/ALT once weekly until resolution to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eIf Grade ≥3 hepatotoxicity recurs, discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHemorrhagic events\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until recovery to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eDiscontinue for severe or life-threatening hemorrhagic events\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eOther adverse reactions\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGrade 3 or 4: Withhold until recovery to Grade ≤2; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrent Grade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eStrong CYP3A4 inhibitors or combined P-gp and strong CYP3A4 inhibitors\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003e\n\u003ch4\u003eDosage modification if unable to avoid combined P-gp and strong CYP3A4 inhibitors\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eIf current pralsetinib dose is 300 or 400 mg qDay, reduce to 200 mg qDay\u003c\/li\u003e\n\u003cli\u003eIf current pralsetinib dose is 200 mg qDay, reduce to 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eAfter inhibitor has been discontinued for 3-5 elimination half-lives, resume at dose taken before initiating combined P-gp and strong CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eStrong CYP3A4 inducers\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unable to avoid, double current pralsetinib dose starting on Day 7 of coadministration with strong CYP3A inducer\u003c\/li\u003e\n\u003cli\u003eAfter inducer has been discontinued for at least 14 days, resume pralsetinib at dose taken before initiating strong CYP3A inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eRenal impairment\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;15 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHepatic impairment\u003c\/h3\u003e\u003cul\u003e\u003cli\u003eMild (total bilirubin less than or equal to ULN and AST \u0026gt; ULN or total bilirubin \u0026gt; 1 to 1.5 × ULN and any AST), moderate (total bilirubin \u0026gt; 1.5 to 3 × ULN and any AST) or severe (total bilirubin \u0026gt; 3 × ULN and any AST): No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797949837355,"sku":"RL2820240816720","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-08-1279.jpg?v=1787022138"},{"product_id":"generic-enasidenib-luciena","title":"MEKTODK (Binimetinib)","description":"\u003ch3\u003eMelanoma\u003c\/h3\u003e\u003cp\u003eIndicated in combination with encorafenib for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation\u003c\/p\u003e\u003cp\u003e45 mg PO BID in combination with encorafenib until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eSee encorafenib drug monograph for recommended dosing information\u003c\/p\u003e\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with encorafenib for patients with unresectable or metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation\u003c\/p\u003e\u003cp\u003e45 mg PO BID in combination with encorafenib until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eSee encorafenib drug monograph for recommended dosing information\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eIf encorafenib is permanently discontinued, discontinue binimetinib\u003c\/p\u003e\u003ch4\u003eRecommended dose reductions for binimetinib for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 30 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSubsequent modifications: Permanently discontinue if unable to tolerate 30 mg\/day\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCardiomyopathy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAsymptomatic, absolute decrease in left ventricular ejection fraction (LVEF) of \u0026gt;10% from baseline that is also below lower limit of normal (LLN): Withhold for up to 4 weeks, evaluate LVEF q2Weeks\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eResume at a reduced dose if the following are present\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eLVEF is at or above the LLN and\u003c\/li\u003e\n\u003cli\u003eAbsolute decrease from baseline is ≤10% and\u003c\/li\u003e\n\u003cli\u003ePatient is asymptomatic\u003c\/li\u003e\n\u003cli\u003eIf the LVEF does not recover within 4 weeks permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eSymptomatic congestive heart failure or absolute decrease in LVEF of greater than \u0026gt;20% from baseline that is also below LLN: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eVenous thromboembolism\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eUncomplicated DVT or PE\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold drug; if improves to Grade 0-1, resume at a reduced dose\u003c\/li\u003e\n\u003cli\u003eIf no improvement, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eLife-threatening PE: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eSerous retinopathy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSymptomatic serous retinopathy\/retinal pigment epithelial detachments\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eWithhold drug for up to 10 days\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eIf improves and becomes asymptomatic, resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf not improved, resume at a lower dose or permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRetinal vein occlusion\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eUveitis\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrades 1-3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eIf Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold for up to 6 weeks; if improved, resume at same or reduced dose\u003c\/li\u003e\n\u003cli\u003eIf not improved, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInterstitial lung disease\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold for up to 4 weeks; if improved to Grade 0-1, resume at a reduced dose\u003c\/li\u003e\n\u003cli\u003eIf not resolved within 4 weeks, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eGrades 3 or 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2 AST\/ALT increased\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eMaintain binimetinib dose; if no improvement within 2 weeks, withhold dose until improved to Grade 0-1 or to pretreatment\/baseline levels and then resume at the same dose\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent Grade 2 or first occurrence of any Grade 3 AST\/ALT increased\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold for up to 4 weeks; if improves to Grade 0-1 or to pretreatment\/baseline level, resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eIf no improvement, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFirst occurrence of any Grade 4 AST\/ALT increased\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePermanently discontinue OR\u003c\/li\u003e\n\u003cli\u003eWithhold for up to 4 weeks; if improves to Grade 0-1 or to pretreatment\/baseline level, resume at reduced dose; if no improvement, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent Grade 3 AST\/ALT increased\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eConsider permanently discontinuing\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent Grade 4 AST\/ALT increased\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRhabdomyolysis or CPK elevations\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 4 asymptomatic CPK elevation OR any Grade CPK elevation with symptoms or with renal impairment\u003c\/li\u003e\n\u003cli\u003eWithhold dose for up to 4 weeks; if improved to Grade 0-1 resume at a reduced dose\u003c\/li\u003e\n\u003cli\u003eIf not resolved within 4 weeks, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDermatologic\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2: If no improvement within 2 weeks, withhold drug until Grade 0-1; resume at same dose if first occurrence or reduce dose if recurrent\u003c\/li\u003e\n\u003cli\u003eGrade 3: Withhold until Grade 0-1; resume at same dose if first occurrence or reduce dose if recurrent\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions, including hemorrhage\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDose modification when administered with encorafenib is NOT recommended for palmarplantar erythrodysesthesia syndrome (PPES), noncutaneous RAS mutation-positive malignancies, and QTc prolongation\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent Grade 2 or first occurrence of any Grade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold for up to 4 weeks; if improves to Grade 0-1 or to pretreatment\/baseline level, resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eIf no improvement, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFirst occurrence of any Grade 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePermanently discontinue OR\u003c\/li\u003e\n\u003cli\u003eWithhold for up to 4 weeks; if improves to Grade 0-1 or to pretreatment\/baseline level, resume at reduced dose; if no improvement, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent Grade 3\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eConsider permanently discontinuing\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent Grade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eModerate (total bilirubin \u0026gt;1.5 to ≤3 x ULN and any AST): 30 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSevere (total bilirubin \u0026gt;3 x ULN and any AST): 30 mg PO BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eNo clinically important changes in binimetinib exposure were observed with severe renal impairment as compared with patients with normal renal function\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eLimitations of use: Not indicated for patient with wild-type BRAF melanoma\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMelanoma: Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens before initiating\u003c\/li\u003e\n\u003cli\u003eNSCLC: Confirm the presence of a BRAF V600E mutation in tumor specimens before initiating\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797950525483,"sku":"RL2620240701","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-06-2421.jpg?v=1787022154"},{"product_id":"generic-entrectinib-entredx-200","title":"ENTREDX 200 (entrectinib)","description":"\u003cdiv class=\"collapse-more\"\u003e\u003ch3\u003eNon-small Cell Lung Cancer\u003c\/h3\u003e\u003c\/div\u003e\u003cp\u003eIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are ROS1-positive\u003c\/p\u003e\u003cp\u003e600 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eNeurotrophic Tyrosine Receptor Kinase Gene Fusion Solid Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and progressed following treatment or have no satisfactory alternative therapy\u003c\/p\u003e\u003cp\u003e600 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 400 mg qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if toxicities persist or recur following 2 dose reductions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCongestive heart failure\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2 or 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCentral nervous system effects\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIntolerable Grade 2: Withhold until recovered to Grade ≤1; resume at reduced dose, as clinically appropriate\u003c\/li\u003e\n\u003cli\u003eGrade 3: Withhold until recovered to Grade ≤1; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3\u003cul\u003e\n\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduced dose;\u003c\/li\u003e\n\u003cli\u003eIf resolution occurs within 4 weeks, resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf adverse reaction persists after 4 weeks, permanently discontinue\u003c\/li\u003e\n\u003cli\u003eFor recurrent Grade 3 events that resolve within 4 weeks, resume at a reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovered to Grade ≤1; resume at reduce dose;\u003c\/li\u003e\n\u003cli\u003eIf adverse reaction does not resolve within 4 weeks or Grade 4 events recurs, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eElevated ALT or AST\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eALT or AST \u0026gt;3x ULN with concurrent total bilirubin \u0026gt;1.5x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHyperuricemia\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSymptomatic or Grade 4: Initiate urate-lowering therapy; withhold until improvement of signs or symptoms; resume at same or reduced dose\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eQTc prolongation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eQTc \u0026gt;500 ms\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until QTc interval recovers to baseline\u003c\/li\u003e\n\u003cli\u003eResume at same dose if causes of QT prolongation are identified and corrected\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose if other causes of QT prolongation are not identified\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eLife-threatening arrhythmia\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eTorsade de pointes; polymorphic ventricular tachycardia; signs\/symptoms of serious arrhythmia: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eVision disorders\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade ≥2: Withhold until improvement or stabilization; resume at same dose or reduced dose, as clinically appropriate\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eAnemia or neutropenia\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until recovery to Grade≤2; resume at same or reduced dose, as clinically appropriate\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eOther clinically relevant adverse reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eGrade 3 or 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until adverse reaction resolves to Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at same or reduced dose if resolved within 4 weeks\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if adverse reaction does not resolve within 4 weeks or Grade 4 events recurs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eCoadministration of moderate and strong CYP3A inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIf coadministration is unavoidable, reduce entrectinib dose as follows:\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eModerate CYP3A Inhibitors: 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eStrong CYP3A Inhibitors: 100 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eAfter discontinuation of strong or moderate CYP3A inhibitor for 3-5 elimination half-lives, resume entrectinib dose taken prior to initiating the CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30 to \u0026lt;90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin ≤1.5x ULN): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe (total bilirubin \u0026gt;1.5x ULN): Not studied; consider risk-benefit profile prior to determining whether to administer therapy to patients with moderate to severe hepatic impairment; monitor for adverse reactions in patients with hepatic impairment more frequently; these patients may be at increased risk for adverse reactions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNSCLC: Presence of ROS1 rearrangement\u003c\/li\u003e\n\u003cli\u003eLocally advanced or metastatic solid tumors: Presence of a NTRK gene fusion\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797951770667,"sku":"RL2020231212780","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1268.jpg?v=1787022160"},{"product_id":"generic-larotrectinib-larotreni-100","title":"Larotreni 100 (Larotrectinib)","description":"\u003cp\u003eLarotrectinib is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change. You might have larotrectinib for a solid cancer if: your cancer is locally advanced or advanced (metastatic) surgery to remove the cancer could cause severe health problems.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Solid_Tumors\"\u003eSolid Tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003e100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Body_Surface_Area_BSA_1_m2\"\u003eBody Surface Area (BSA) ≥1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797951836203,"sku":"RL2020231212933","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1469.jpg?v=1787022161"},{"product_id":"generic-selpercatinib-sepadx","title":"SEPADX (Selpercatinib)","description":"\u003cp\u003eThe targeted drug selpercatinib  has been a treatment option for some people with lung cancer or thyroid cancer whose tumors contain specific changes in a gene called \u003cem\u003eRET\u003c\/em\u003e.\u003c\/p\u003e\u003ch3\u003eNon-small Cell Lung Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic RET fusion-positive non-small cell lung cancer (NSCLC)\u003c\/p\u003e\u003cp\u003e\u0026lt;50 kg: 120 mg PO BID\u003c\/p\u003e\u003cp\u003e≥50 kg: 160 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eMedullary Thyroid Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for advanced or metastatic RET-mutant medullary thyroid cancer (MTC) in patients who required systemic therapy\u003c\/p\u003e\u003cp\u003e\u0026lt;50 kg: 120 mg PO BID\u003c\/p\u003e\u003cp\u003e≥50 kg: 160 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eThyroid Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for advanced or metastatic RET fusion-positive thyroid cancer in patients who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)\u003c\/p\u003e\u003cp\u003e\u0026lt;50 kg: 120 mg PO BID\u003c\/p\u003e\u003cp\u003e≥50 kg: 160 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eOther RET Fusion-Positive Solid Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options\u003c\/p\u003e\u003cp\u003e\u0026lt;50 kg: 120 mg PO BID\u003c\/p\u003e\u003cp\u003e≥50 kg: 160 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reduction recommendations\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eWeight \u0026lt;50 kg\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst reduction: 80 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 40 mg BID\u003c\/li\u003e\n\u003cli\u003eThird reduction: 40 mg qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if unable to tolerate third dose reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eWeight ≥50 kg\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst reduction: 120 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 80 mg BID\u003c\/li\u003e\n\u003cli\u003eThird reduction: 40 mg BID\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if unable to tolerate third dose reduction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity grade 3 or 4\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold dosing and monitor AST\/ALT once weekly until resolution to Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose by 2 dose levels and monitor AST\/ALT once weekly until 4 weeks after reaching dose taken prior to the onset of Grade 3 or 4 increased AST or ALT\u003c\/li\u003e\n\u003cli\u003eIncrease dose by 1 dose level after a minimum of 2 weeks without recurrence, and then increase to dose taken before Grade 3 or 4 increased AST or ALT after minimum of 4 weeks without recurrence\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInterstitial lung disease\/ pneumonitis\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2: Withhold until resolution; resume at a reduced dose; discontinue for recurrent ILD\/pneumonitis\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4: Discontinue for confirmed ILD\/pneumonitis\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHypothyroidism\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until resolution to Grade 1 or baseline; discontinue based on severity\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eHypertension\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold dosing for Grade 3 hypertension that persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension controlled\u003c\/li\u003e\n\u003cli\u003eGrade 4: Discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eQT prolongation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold dosing until recovery to baseline or Grade ≤1; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHemorrhagic events grade 3 or 4\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold dosing until recovery to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eDiscontinue for severe or life-threatening hemorrhagic events\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHypersensitivity reactions all grades\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold dosing until resolution; initiate corticosteroids\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose by 3 dose levels while continuing corticosteroids\u003c\/li\u003e\n\u003cli\u003eIncrease dose by 1 dose level each week until the dose taken prior to hypersensitivity event is reached, then taper corticosteroids\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse effects grade 3 or 4\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold dosing until recovery to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCoadministration with CYP3A inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration; if unable to avoid, reduce selpercatinib dose\u003c\/li\u003e\n\u003cli\u003eAfter inhibitor has been discontinued for 3-5 elimination half-lives, resume selpercatinib at dose take prior to initiated the CYP3A inhibitor\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eModerate CYP3A inhibitor\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eIf current dose is 120 mg BID, reduce to 80 mg BID\u003c\/li\u003e\n\u003cli\u003eIf current dose is 160 mg BID, reduce to 120 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eStrong CYP3A inhibitor\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eIf current dose is 120 mg BID, reduce to 40 mg BID\u003c\/li\u003e\n\u003cli\u003eIf current dose is 160 mg BID, reduce to 80 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-severe (CrCl ≥15 mL\/min): No dose adjustment required\u003c\/li\u003e\n\u003cli\u003eESRD: Recommended dose not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eMild or moderate\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eNo dose adjustment required\u003c\/li\u003e\n\u003cli\u003eMild defined as: TB ≤ULN with AST \u0026gt;ULN OR TB \u0026gt;1-1.5x ULN with any AST\u003c\/li\u003e\n\u003cli\u003eModerate defined as: TB \u0026gt;1.5-3x ULN with any AST\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eSevere\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eIf current dose is 120 mg or 160 mg BID, reduce to 80 mg BID\u003c\/li\u003e\n\u003cli\u003eSevere defined as: Total biliruvin (TB) \u0026gt;3-10x ULN with any AST\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eAcid-reducing agents\u003c\/h4\u003e\u003cp\u003eAvoid with PPIs, histamine-2 (H2) receptor antagonists, or locally acting antacids\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eIf unable to avoid\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePPIs: Take with food when coadministered\u003c\/li\u003e\n\u003cli\u003eH2 receptor antagonist: Take selpercatinib 2 hr before or 10 hr after an H2 antagonist\u003c\/li\u003e\n\u003cli\u003eLocally acting antacid: Take selpercatinib 2 hr before or 2 hr after antacid\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eSelect patients for treatment based on presence of RET gene fusion (NSCLC or thyroid cancer) or specific RET gene mutation (MTC) in tumor specimens or plasma\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797951901739,"sku":"RL2020231216786","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1547.jpg?v=1787022163"},{"product_id":"loqtorzi-toripalimab","title":"Loqtorzi (Toripalimab)","description":"\u003ch2\u003eAbout Toripalimab\u003c\/h2\u003e\u003cp\u003eToripalimab-tpzi is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD⁠-⁠1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab  sold under the brand name LOQTORZI\u003csup\u003e®\u003c\/sup\u003e in Europe.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name ZYTORVI\u003csup\u003e®\u003c\/sup\u003e in India.\u003c\/li\u003e\n\u003cli\u003eToripalimab  sold under the brand name 拓益\u003csup\u003e®\u003c\/sup\u003e in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eApproved\u003c\/h2\u003e\u003ch3\u003eOn October 27, 2023\u003c\/h3\u003e\u003cp\u003eThe FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).\u003c\/p\u003e\u003cp\u003eFDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.\u003c\/p\u003e\u003ch3\u003eSeptember 24, 2024\u003c\/h3\u003e\u003cp\u003eShanghai -- On September 24, 2024, Beijing time, Junshi Biosciences (1877.HK, 688180.SH) announced that the company's independently developed anti-PD-1 monoclonal antibody drug Toripalimab (European trade name: LOQTORZI®) has recently been approved by the European Commission (EC) for the treatment of two indications:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eToripalimab combined with cisplatin and gemcitabine is used for the first-line treatment of adult patients with recurrent, inoperable or radiotherapy-intolerant, or metastatic nasopharyngeal carcinoma (NPC);\u003c\/li\u003e\n\u003cli\u003eToripalimab combined with cisplatin and paclitaxel is used for the first-line treatment of adult patients with unresectable advanced\/recurrent or metastatic esophageal squamous cell carcinoma (ESCC).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Junshi Biosciences, China","offers":[{"title":"Default Title","offer_id":44797952229419,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-22100.jpg?v=1787022170"},{"product_id":"avzivi-bevacizumab","title":"Avzivi (Bevacizumab)","description":"\u003cp\u003eAvzivi® (Bevacizumab-tnjn)  sold under the brand name POBEVCY (普贝希) in China, is a humanized monoclonal antibody that targets VEGF. It specifically binds to VEGF and blocks the binding of VEGF to its receptor, thereby reducing neovascularization, inducing the degradation of existing blood vessels, and thereby inhibiting tumor growth. \u003c\/p\u003e\u003cp\u003eDec 7, 2023，The FDA has approved the fifth bevacizumab biosimilar, Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) for the treatment of several types of cancer. Avzivi\u003csup\u003e®\u003c\/sup\u003e (BAT1706) is Bio-Thera Solutions’ second FDA approved product in the United States. Avzivi\u003csup\u003e®\u003c\/sup\u003e is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.\u003c\/p\u003e","brand":"Bio-Thera Solutions, China","offers":[{"title":"Default Title","offer_id":44797952360491,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-2233.png?v=1787022174"},{"product_id":"zerpidio-serplulimab","title":"Zerpidio (Serplulimab)","description":"Serplulimab, a recombinant humanised anti-PD-1 monoclonal antibody (mAb) injection, is the first innovative monoclonal antibody developed by Henlius.\r\n\u003cul\u003e\r\n \t\u003cli\u003eSerplulimab sold under the brand name 汉斯状\u003csup\u003e®\u003c\/sup\u003e in china.\u003c\/li\u003e\r\n \t\u003cli\u003eSerplulimab sold under the brand name Hetronifly\u003csup\u003e®\u003c\/sup\u003e in Euro.\u003c\/li\u003e\r\n \t\u003cli\u003eSerplulimab sold under the brand name Zerpidio\u003csup\u003e®\u003c\/sup\u003e in other Place.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nIt has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of Small Cell Lung Cancer (SCLC). Its marketing application for the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) is under review by the EMA.\r\n\r\nSerplulimab was launched in \u003cspan class=\"xn-location\"\u003eChina\u003c\/span\u003e under the trade name HANSIZHUANG（汉斯状） in \u003cspan class=\"xn-chron\"\u003eMarch 2022\u003c\/span\u003e and has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, and esophageal squamous cell carcinoma (ESCC).\r\n\r\n\u003cspan class=\"legendSpanClass\"\u003e\u003cspan class=\"xn-chron\"\u003eOct. 27, 2023\u003c\/span\u003e\u003c\/span\u003e - Intas Pharmaceuticals Limited (\"Intas\") has entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the development and commercialisation of serplulimab for \u003cspan class=\"xn-location\"\u003eEurope\u003c\/span\u003e and \u003cspan class=\"xn-location\"\u003eIndia\u003c\/span\u003e markets.\r\n\r\n\u003cspan class=\"legendSpanClass\"\u003e\u003cspan class=\"xn-chron\"\u003eJan. 25, 2024 \u003c\/span\u003e\u003c\/span\u003eZerpidio\u003csup\u003e®\u003c\/sup\u003e start set sail for \u003cspan class=\"xn-location\"\u003eIndonesia\u003c\/span\u003e. Zerpidio® in Indonesia for the treatment of extensive stage small cell lung cancer (ES-SCLC).","brand":"Henlius Biopharmaceutical Company","offers":[{"title":"Default Title","offer_id":44797952393259,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-3152.png?v=1787022175"},{"product_id":"e6-9b-bf-e9-9b-b7-e5-88-a9-e7-8f-a0-e5-8d-95-e6-8a-97-ef-bc-88tislelizumab-ef-bc-89","title":"Tevimbra（Tislelizumab）","description":"Tevimbra (Tislelizumab-jsgr) sold under the brand name \u003cstrong\u003e百泽安\u003c\/strong\u003e in china, is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.\r\n\r\nThe FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) following prior systemic chemotherapy that did not include a PD-1\/PD-L1 inhibitor.","brand":"BeiGene Biotechnology, China","offers":[{"title":"Default Title","offer_id":44797952589867,"sku":"RL2320301801","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-03-1610.png?v=1787022181"},{"product_id":"generic-larotrectinib-larodx-25","title":"LARODX 25 (Larotrectinib)","description":"\u003ch2\u003eLarotrectinib\u003c\/h2\u003e\u003cp\u003eLarotrectinib is a medication for the treatment of cancer.\u003csup id=\"cite_ref-Vitrakvi_AU_summary_4-0\" class=\"reference\"\u003e\u003c\/sup\u003eIt is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.\u003csup id=\"cite_ref-pmid30069765_7-0\" class=\"reference\"\u003e\u003c\/sup\u003e \u003c\/p\u003e\u003cp\u003eLarotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.\u003c\/p\u003e\u003cp\u003eLarotrectinib was the first drug to be specifically developed and approved to treat \u003ci\u003eany\u003c\/i\u003e cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is \"tissue agnostic\"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.\u003csup id=\"cite_ref-14\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003eADULT\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003eDosage Forms \u0026amp; Strengths\u003c\/h3\u003e\n\u003ch4\u003ecapsule\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eoral solution\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003eSolid Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003e100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eBody Surface Area (BSA) ≥1 m2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eGrade ≥3 adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modification\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inducers\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken prior to initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003ePEDIATRIC\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003eDosage Forms \u0026amp; Strengths\u003c\/h3\u003e\n\u003ch4\u003ecapsule\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003eoral solution\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003eSolid Tumors\u003c\/h3\u003e\u003cp\u003endicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003eBody surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Pediatric Dosing \u0026amp; Uses\" data-text=\"Body surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003cp\u003eBSA ≥1 m\u003csup\u003e2\u003c\/sup\u003e: 100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eBSA \u0026lt;1 m2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Not to exceed 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID; remain on 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID even if BSA becomes \u0026gt;1 m\u003csup\u003e2\u003c\/sup\u003e during treatment\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eBSA ≥1 m2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eGrade ≥3 adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modificatio\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong CYP3A4 inducers\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797952950315,"sku":"RL2620240606","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-05-3027.jpg?v=1787022187"},{"product_id":"generic-larotrectinib-larodx-100","title":"LARODX 100 (Larotrectinib)","description":"\u003ch2\u003e\u003cspan id=\"Larotrectinib\"\u003eLarotrectinib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eLarotrectinib is a medication for the treatment of cancer.\u003csup id=\"cite_ref-Vitrakvi_AU_summary_4-0\" class=\"reference\"\u003e\u003c\/sup\u003eIt is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.\u003csup id=\"cite_ref-pmid30069765_7-0\" class=\"reference\"\u003e\u003c\/sup\u003e \u003c\/p\u003e\u003cp\u003eLarotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.\u003c\/p\u003e\u003cp\u003eLarotrectinib was the first drug to be specifically developed and approved to treat \u003ci\u003eany\u003c\/i\u003e cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is \"tissue agnostic\"). Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.\u003csup id=\"cite_ref-14\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"ADULT\"\u003eADULT\u003c\/span\u003e\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003e\u003cspan id=\"Dosage_Forms_Strengths\"\u003eDosage Forms \u0026amp; Strengths\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch4\u003e\u003cspan id=\"capsule\"\u003ecapsule\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003e\u003cspan id=\"oral_solution\"\u003eoral solution\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003e\u003cspan id=\"Solid_Tumors\"\u003eSolid Tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003e100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Body_Surface_Area_BSA_1_m2\"\u003eBody Surface Area (BSA) ≥1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Grade_3_adverse_reactions\"\u003eGrade ≥3 adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modification\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inhibitors\"\u003eStrong CYP3A4 inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inducers\"\u003eStrong CYP3A4 inducers\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken prior to initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Patient_selection\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"PEDIATRIC\"\u003ePEDIATRIC\u003c\/span\u003e\u003c\/h2\u003e\u003cdiv class=\"collapse-more\"\u003e\n\u003ch3\u003e\u003cspan id=\"Dosage_Forms_Strengths1\"\u003eDosage Forms \u0026amp; Strengths\u003c\/span\u003e\u003c\/h3\u003e\n\u003ch4\u003e\u003cspan id=\"capsule1\"\u003ecapsule\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e25mg\u003c\/li\u003e\n\u003cli\u003e100mg\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch4\u003e\u003cspan id=\"oral_solution1\"\u003eoral solution\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\u003cli\u003e20mg\/mL\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv id=\"str-native-pl-421\" class=\"Adunit-sfp\"\u003e\u003cdiv id=\"str-native-cont-421\"\u003e \u003c\/div\u003e\u003c\/div\u003e\u003ch3\u003e\u003cspan id=\"Solid_Tumors1\"\u003eSolid Tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003endicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\u003c\/p\u003e\u003cp\u003eBody surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Pediatric Dosing \u0026amp; Uses\" data-text=\"Body surface area (BSA) \u0026lt;1 m2: 100 mg\/m2 PO BID\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003cp\u003eBSA ≥1 m\u003csup\u003e2\u003c\/sup\u003e: 100 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or until unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications1\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dosage_modifications_for_adverse_reactions1\"\u003eDosage modifications for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"BSA_1_m2\"\u003eBSA \u0026lt;1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Not to exceed 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID; remain on 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID even if BSA becomes \u0026gt;1 m\u003csup\u003e2\u003c\/sup\u003e during treatment\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 25 mg\/m\u003csup\u003e2\u003c\/sup\u003e BID: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003e\u003cspan id=\"BSA_1_m21\"\u003eBSA ≥1 m2\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\n\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Grade_3_adverse_reactions1\"\u003eGrade ≥3 adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold until reaction resolves or improves to baseline or Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResolved within 4 weeks: Resume at next dosage modificatio\u003c\/li\u003e\n\u003cli\u003eUnresolved within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inhibitors1\"\u003eStrong CYP3A4 inhibitors\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, reduce larotrectinib dose by 50%\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inhibitor is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Strong_CYP3A4_inducers1\"\u003eStrong CYP3A4 inducers\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf unavoidable, double larotrectinib dose\u003c\/li\u003e\n\u003cli\u003eOnce strong CYP3A4 inducer is discontinued for 3-5 elimination half-lives, resume larotrectinib at dose taken before initiating CYP3A4 inducer\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment1\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate to severe (Child-Pugh B or C): Reduce starting dose by 50%\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment1\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild to severe: No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosing_Considerations1\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eVerify pregnancy status in females of reproductive potential before initiation\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Patient_selection1\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eSelect patients based on presence of a NTRK gene fusion in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797952983083,"sku":"RL2620240606","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-05-3069.jpg?v=1787022188"},{"product_id":"generic-crizotinib-kesodx","title":"KESODX (Crizotinib)","description":"\u003ch2\u003eABout Crizotinib \u003c\/h2\u003e\u003cp\u003eCrizotinib is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Non-Small_Cell_Lung_Cancer\"\u003eNon-Small Cell Lung Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kinase (ALK)- or ROS1-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Inflammatory_Myofibroblastic_tumors\"\u003eInflammatory Myofibroblastic tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable, recurrent, or refractory inflammatory myofibroblastic tumors (IMT) in adults who are ALK-positive\u003c\/p\u003e\u003cp\u003e250 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 250 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 250 mg PO qDay: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953081387,"sku":"RL3020241020","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-1235-jpg.webp?v=1787022192"},{"product_id":"generic-repotrectinib-repodx-2","title":"REPODX (Repotrectinib)","description":"\u003ch3\u003e\u003cspan id=\"About_Repotrectinib\"\u003eAbout Repotrectinib\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eRepotrectinib is an anti-cancer medication used for the treatment of non-small cell lung cancer. It is taken by mouth. Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1 (\u003ci\u003eROS1\u003c\/i\u003e) and of the tropomyosin receptor tyrosine kinases (TRKs) TRKA, TRKB, and TRKC.\u003csup id=\"cite_ref-Augtyro_FDA_label_1-3\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Non-small_Cell_Lung_Cancer\"\u003eNon-small Cell Lung Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)\u003c\/p\u003e\u003cp\u003e160 mg PO qDay for 14 days, then increase to 160 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"NTRK_Fusion-Positive_Solid_Tumors\"\u003eNTRK Fusion-Positive Solid Tumors\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for locally advanced, metastatic, or inoperable (surgical resection likely to result in severe morbidity) solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion that have progressed following treatment or have no satisfactory alternative treatment options\u003c\/p\u003e\u003cp\u003e160 mg PO qDay for 14 days, then increase to 160 mg PO BID\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dose_reductions_for_adverse_reactions\"\u003eDose reductions for adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Current_dose_is_160_mg_PO_qDay\"\u003eCurrent dose is 160 mg PO qDay\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 120 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 80 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Current_dose_is_160_mg_PO_BID\"\u003eCurrent dose is 160 mg PO BID\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 120 mg PO BID\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 80 mg PO BID\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Central_nervous_system_effects\"\u003eCentral nervous system effects\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIntolerable grade 2: Withhold until grade ≤1 or baseline; resume at same or reduced dose, as clinically appropriate\u003c\/li\u003e\n\u003cli\u003eGrade 3: Withhold until grade ≤1; resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Interstitial_lung_disease_ILD\"\u003eInterstitial lung disease (ILD)\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSuspected ILD: Withhold\u003c\/li\u003e\n\u003cli\u003eConfirmed ILD: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatotoxicity\"\u003eHepatotoxicity\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eALT or AST \u0026gt;3x ULN with concurrent total bilirubin \u0026gt;1.5x ULN (without cholestasis or hemolysis): Permanently discontinue\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_3\"\u003eGrade 3\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at same dose if resolves within 4 weeks\u003c\/li\u003e\n\u003cli\u003eRecurrent grade 3 that resolves within 4 weeks: Resume at a reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_4\"\u003eGrade 4\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eReaction does not resolve within 4 weeks OR recurrent grade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Creatine_phosphokinase_CPK_elevation\"\u003eCreatine phosphokinase (CPK) elevation\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Withhold_until_resolves_to_baseline_or_25x_ULN_then\"\u003eWithhold until resolves to baseline or ≤2.5x ULN, then\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eCPK elevation \u0026gt;5x ULN: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eCPK elevation \u0026gt;10x ULN or second occurrence of CPK elevation \u0026gt;5x ULN: Resume at reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hyperuricemia\"\u003eHyperuricemia\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Withhold until signs and symptoms improve, then resume at same or reduced dose\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_significant_adverse_reactions\"\u003eOther significant adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIntolerable grade 2 \u003ci\u003eor\u003c\/i\u003e grade 3 or 4: Withhold until grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eResolves within 4 weeks: Resume at same or reduced dose\u003c\/li\u003e\n\u003cli\u003eDoes not resolve within 4 weeks: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (eGFR 30-90 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR \u0026lt;30 mL\/min) or patients on dialysis: Dosage guidance not provided; pharmacokinetic data unknown\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin \u0026gt;1-1.5x ULN or AST \u0026gt;ULN): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate or severe (total bilirubin \u0026gt;1.5x ULN with any AST): Dosage guidance not provided; pharmacokinetic data unknown\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003e\u003cspan id=\"Dosing_Considerations\"\u003eDosing Considerations\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Before_initiating\"\u003eBefore initiating\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDiscontinue strong or moderate CYP3A4 inhibitors for 3-5 half-lives of CYP3A4 inhibitor\u003c\/li\u003e\n\u003cli\u003eEvaluate liver function tests and uric acid levels\u003c\/li\u003e\n\u003cli\u003eVerify pregnancy status of females of childbearing potential before initiating\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Patient_selection\"\u003ePatient selection\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"NSCLC\"\u003eNSCLC\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003e\u003cp\u003eVerify presence of ROS1 rearrangements in tumor specimens\u003c\/p\u003e\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Other_solid_tumors\"\u003eOther solid tumors\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eVerify presence of NTRK1\/2\/3 rearrangements in tumor specimens\u003c\/li\u003e\n\u003cli\u003eConsider treatment without confirmation of NTRK1\/2\/3 rearrangements in patients with secretory breast cancer or mammary analogue secretory cancer\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953146923,"sku":"RL3020241020","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-1224-jpg.webp?v=1787022193"},{"product_id":"generic-encorafenib-bratodx","title":"BRATODX (Encorafenib)","description":"\u003ch3\u003eAbout Encorafenib\u003c\/h3\u003e\u003cp\u003eEncorafenib is a medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.\u003c\/p\u003e\u003ch3\u003eMelanoma\u003c\/h3\u003e\u003cp\u003eIndicated in combination with binimetinib for unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation, as detected by an FDA-approved test\u003c\/p\u003e\u003cp\u003e450 mg PO qDay in combination with binimetinib\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eSee binimetinib drug monograph for recommended dosing information\u003c\/p\u003e\u003ch3\u003eNon-Small Cell Lung Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with binimetinib for unresectable or metastatic non-small cell lung cancer (NSCLC) in patients with a BRAF V600E mutation, as detected by an FDA-approved test\u003c\/p\u003e\u003cp\u003e450 mg PO qDay in combination with binimetinib\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eSee binimetinib drug monograph for recommended dosing information\u003c\/p\u003e\u003ch3\u003eMetastatic Colorectal Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with cetuximab for metastatic colorectal cancer (CRC) in patients with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy\u003c\/p\u003e\u003cp\u003e300 mg PO qDay in combination with cetuximab\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eSee cetuximab drug monograph for recommended dosing information\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953212459,"sku":"RL3020241020","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-1273-jpg.webp?v=1787022195"},{"product_id":"generic-tepotinib-tepodx","title":"TEPODX (Tepotinib)","description":"\u003ch2\u003eAbout Tepotinib\u003c\/h2\u003e\u003cp\u003eTepotinib is a kinase inhibitor directed against MET, including variants with exon 14 skipping - it inhibits MET phosphorylation and subsequent downstream signaling pathways in order to inhibit tumor cell proliferation, anchorage-independent growth, and migration of MET-dependent tumor cells.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Non-Small_Cell_Lung_Cancer\"\u003eNon–Small Cell Lung Cancer\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIndicated for metastatic non–small cell lung cancer (NSCLC) in adults harboring mesenchymal-epithelial transition (MET) exon 14 (ex14) skipping alterations\u003c\/p\u003e\u003cp\u003e450 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eRecommended dose reduction to manage adverse reactions: 225 mg PO qDay\u003c\/p\u003e\u003cp\u003ePermanently discontinue if unable to tolerate 225 mg PO qDay\u003c\/p\u003e\u003ch4\u003e\u003cspan id=\"Interstitial_lung_disease_ILD_pneumonitis\"\u003eInterstitial lung disease (ILD)\/ pneumonitis\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSuspected ILD (any grade): Withhold\u003c\/li\u003e\n\u003cli\u003eConfirmed ILD: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Increased_ASTALT_andor_total_bilirubin\"\u003eIncreased AST\/ALT and\/or total bilirubin\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_3_increased_ASTALT_without_increased_total_bilirubin\"\u003eGrade 3 increased AST\/ALT without increased total bilirubin\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to baseline ALT\/AST\u003c\/li\u003e\n\u003cli\u003eIf recovered to baseline ≤7 days, resume at same dose; otherwise, resume at a reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Grade_3_increased_total_bilirubin_without_concurrent_increased_ASTALT\"\u003eGrade 3 increased total bilirubin without concurrent increased AST\/ALT\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to baseline total bilirubin\u003c\/li\u003e\n\u003cli\u003eIf recovered to baseline ≤7 days, resume at reduced dose; otherwise, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Permanently_discontinue\"\u003ePermanently discontinue\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eGrade 4 increased ALT\/AST without increased total bilirubin\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN with total bilirubin \u0026gt;2x ULN without cholestasis or hemolysis\u003c\/li\u003e\n\u003cli\u003eGrade 4 increased total bilirubin without concurrent increased AST\/ALT\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Other_adverse_reactions\"\u003eOther adverse reactions\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 2: Maintain dose; if intolerable, consider withholding until resolved, then resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 3: Withhold until resolved, then resume at reduced dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Recommended dose not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (Child-Pugh Class A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh Class C): Pharmacokinetics and safety not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953507371,"sku":"RL3020241030","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2296.jpg?v=1787022203"},{"product_id":"e4-be-9d-e8-be-be-e6-96-b9-ivonescimab-injection","title":"Ivonescimab","description":"\u003ch2\u003eAbout Ivonescimab\u003c\/h2\u003e\u003cp\u003eIvonescimab is the most advanced PD-1\/VEGF bispecific antibody in clinical development in the U.S., Canada, Europe, Japan \u0026amp; Latin America and is an investigational therapy that is not approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).\u003c\/p\u003e\u003cp\u003eIt brings two validated mechanisms in oncology3-5 into ONE novel tetravalent molecule. Ivonescimab simultaneously engages both PD-1 \u0026amp; VEGF. Globally over 1,800+ have been treated with ivonescimab across all clinical trials to date.\u003c\/p\u003e\u003cul\u003e\u003cli\u003eIvonescimab sold as brand name 依达方® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003eEffect\u003c\/h2\u003e\u003cp\u003eEffect of ivonescimab monotherapy in patients with PD-L1-positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC)\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\u003ca href=\"https:\/\/www.akesobio.com\/en\/media\/akeso-news\/240908\/\"\u003eWCLC 2024 | Akeso's Ivonescimab Head-to-Head Phase III Data Against Pembrolizumab Unveiled\u003c\/a\u003e\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage and administration\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIvonescimab is administered by intravenous infusion.\u003c\/p\u003e\u003cp\u003eThe recommended dose is 20 mg\/kg, once every 3 weeks, until disease progression or unacceptable toxicity occurs.\u003c\/p\u003e\u003cp\u003eWhen Ivonescimab is administered in combination with chemotherapy drugs, Ivonescimab should be given first, with an interval of at least 30 minutes, followed by chemotherapy drugs. See also the prescribing information for chemotherapy drugs.\u003c\/p\u003e\u003cp\u003eAtypical efficacy responses may be observed (e.g., temporary tumor enlargement or new lesions in the first few months of treatment, followed by tumor shrinkage); if the patient's clinical symptoms are stable or continue to improve, even if there is preliminary evidence of disease progression on imaging, based on the judgment of overall clinical benefit, continued use of Ivonescimab treatment can be considered until disease progression is confirmed.\u003c\/p\u003e\u003cp\u003eInterruption of dosing or permanent discontinuation may be necessary based on safety and tolerability in the individual patient. Dose increases or decreases are not recommended.\u003c\/p\u003e","brand":"Akesobio, Inc, China","offers":[{"title":"Default Title","offer_id":44797953540139,"sku":"RL2720240718350","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2511.png?v=1787022205"},{"product_id":"ivesa-furmonertinib","title":"Ivesa  (Furmonertinib)","description":"\u003ch2\u003eAbout Furmonertinib\u003c\/h2\u003e\u003cp\u003eFurmonertinib Mesilate acts as an anti-cancer agent. It is formulated as tablets for oral route of administration. Furmonertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eFurmonertinib sold under the brand name Ivesa. \u003c\/li\u003e\n\u003cli\u003eFurmonertinib sold under the brand name 艾弗沙 in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eJune\/2022, Shanghai Allist Pharmaceuticals Co., Ltd. (stock code: 688578) announced that Furmonertinib had been approved by the National Medical Products Administration (NMPA) of China for use in the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage\"\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eThe recommended dose of this product is 80 mg, taken orally once a day until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003eThis product should be taken on an empty stomach. Take this product at approximately the same time every day, swallow the whole tablet with water, do not crush or chew. If the patient misses a dose of this product and it is more than 12 hours before the next dose, the patient should take this product.\u003c\/p\u003e\u003ch3\u003eDosage adjustment\u003c\/h3\u003e\u003cp\u003eIf adverse events occur during the use of this product, the drug can be temporarily interrupted, the dose can be reduced, or the treatment with this product can be stopped according to the specific situation. If a reduction is required, the dose can be reduced to 40 mg, once a day.\u003c\/p\u003e","brand":"Allist Pharmaceuticals, China","offers":[{"title":"Default Title","offer_id":44797953605675,"sku":"RL2320241030285","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2811.png?v=1787022208"},{"product_id":"ameile-aumolertinib","title":"Aumseqa (Aumolertinib)","description":"\u003ch2\u003e\u003cspan id=\"About_Furmonertinib\"\u003eAbout Aumolertinib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eAumseqa (INN: Aumolertinib) (previously known as almonertinib) is a EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eAumolertinib sold under the brand name Ameile. \u003c\/li\u003e\n\u003cli\u003eAumolertinib sold under the brand name 阿美乐 in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eIn March 2020 aumolertinib was approved in China, on the basis of APOLLO (ClinicalTrials.gov identifier: NCT0298110), for the treatment of patients with advanced NSCLC and an EGFR T790M mutation.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage\"\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eThe recommended dose of this product is 110 mg, taken orally once a day until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003eThis product can be taken on an empty stomach or after meals. It is recommended to take it at approximately the same time every day, swallow the whole tablet, and take it with a full glass of water, without chewing or crushing. If you miss a dose of this product, if the next dose is more than 12 hours away, you should take this product.\u003c\/p\u003e\u003ch3\u003eDosage adjustment\u003c\/h3\u003e\u003cp\u003eDepending on the safety and tolerability of the individual patient, the drug can be suspended or reduced. If a dose reduction is required, the dose should be reduced to 55 mg once a day.\u003c\/p\u003e","brand":"HANSOH Pharma, China","offers":[{"title":"Default Title","offer_id":44797953703979,"sku":"RL2320241030250","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-2938.jpg?v=1787022209"},{"product_id":"orpathys-savolitinib","title":"Orpathys (Savolitinib)","description":"\u003ch2\u003e\u003cspan id=\"About_Aumolertinib\"\u003e\u003cspan id=\"About_Furmonertinib\"\u003eAbout Savolitinib\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eSavolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumours. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSavolitinib sold under the brand name Orpathys . \u003c\/li\u003e\n\u003cli\u003eSavolitinib sold under the brand name 沃瑞沙 in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2 id=\"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer\" class=\"title !m-0 break-words text-dark-grey\" data-sb-field-path=\".title\"\u003e\u003cspan id=\"Approval\"\u003eApproval\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eJune 2021, AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dosage\"\u003e\u003cspan id=\"Dosage_and_administration\"\u003eDosage\u003c\/span\u003e\u003c\/span\u003e\u003c\/h2\u003e\u003ch3\u003eRecommended dose and administration\u003c\/h3\u003e\u003cp\u003eFor patients weighing ≥50 kg, the recommended starting dose is 600 mg, taken orally once daily until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003eFor patients weighing \u0026lt;50 kg, the recommended starting dose is 400 mg, taken orally once daily until disease progression or intolerable toxicity occurs.\u003c\/p\u003e\u003cp\u003eIt is recommended to take this product immediately after a meal at the same time every day.\u003c\/p\u003e\u003ch3\u003eDose adjustment\u003c\/h3\u003e\u003cp\u003eDoctors should closely monitor patients during medication and adjust medication according to individual patient safety and tolerability, including suspending this product, reducing the dose, or permanently discontinuing this product.\u003c\/p\u003e","brand":"HUTCHMED, China","offers":[{"title":"Default Title","offer_id":44797953835051,"sku":"RL2320241030","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-291.jpg?v=1787022211"},{"product_id":"generic-afatinib-luciafa","title":"LuciAfa (Afatinib)","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS AND USAGE\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eAfatinib is a kinase inhibitor indicated for:\u003c\/p\u003e\u003cp\u003e• First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.\u003c\/p\u003e\u003cp\u003eLimitations of Use: Safety and efficacy of LuciAfa were not established in patients whose tumors have resistant EGFR mutations .\u003c\/p\u003e\u003cp\u003e• Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy .\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDOSAGE AND ADMINISTRATION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e• Recommended dosage: 40 mg orally once daily.\u003c\/p\u003e\u003cp\u003e• Renal impairment: 30 mg orally once daily in patients with severe renal impairment.\u003c\/p\u003e\u003cp\u003e• Instruct patients to take LuciAfa at least 1 hour before or 2 hours after a meal.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797953998891,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0834.jpg?v=1787022212"},{"product_id":"generic-erlotinib-lucierlo","title":"LuciErlo (Erlotinib)","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS AND USAGE\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eErlotinib is a kinase inhibitor indicated for:\u003c\/p\u003e\u003cp\u003e· The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.\u003c\/p\u003e\u003cp\u003e· First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.\u003c\/p\u003e\u003cp\u003eLimitations of Use:\u003c\/p\u003e\u003cp\u003e· Safety and efficacy of LuciErlo have not been established in patients with NSCLC whose tumors have other EGFR mutations.\u003c\/p\u003e\u003cp\u003e· LuciErlo is not recommended for use in combination with platinumbased chemotherapy.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDOSAGE AND ADMINISTRATION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e· NSCLC: 150 mg orally, on an empty stomach, once daily.\u003c\/p\u003e\u003cp\u003e· Pancreatic cancer: 100 mg orally, on an empty stomach, once daily.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954031659,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0843.jpg?v=1787022214"},{"product_id":"generic-dacomitinib-lucidac","title":"LuciDac (Dacomitinib)","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS AND USAGE\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDOSAGE AND ADMINISTRATION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eRecommended Dosage: 45 mg orally once daily with or without food.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954064427,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-086.jpg?v=1787022215"},{"product_id":"tyvyt-sintilimab","title":"TYVYT  (Sintilimab)","description":"\u003cp\u003eTYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) is a fully human IgG4 monoclonal antibody, which specifically binds to PD-1 expressed on the surface of T cells to block the interaction between PD-L1 and PD-1, thereby reinvigorating exhausted T cell to gain effector function to kill tumor cells.\u003cbr\u003e\u003cbr\u003eIn December 2018, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was first approved by the China NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy.\u003c\/p\u003e\u003cp\u003eIn February 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for the treatment of nonsquamous non-small cell lung cancer.\u003c\/p\u003e\u003cp\u003eIn June 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with gemcitabine and platinum chemotherapy as the first-line therapy for the treatment of squamous non-small cell lung cancer.\u003c\/p\u003e\u003cp\u003eIn June 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the China NMPA in combination with BYVASDA\u003csup\u003e®\u003c\/sup\u003e (bevacizumab biosimilar) as the first-line therapy for the treatment of Hepatocellular Carcinoma.\u003c\/p\u003e\u003cp\u003eIn December 2021, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was the only PD-1 inhibitor in China with four major indications (1L nsq NSCLC, 1L sq NSCLC, 1L HCC and cHL) approved and included in China’s NRDL.\u003c\/p\u003e\u003cp\u003eIn June 2022，TYVYT️\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the NMPA for the fifth indication in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).\u003cbr\u003e\u003cbr\u003eIn June 2022, TYVYT\u003csup\u003e®\u003c\/sup\u003e (sintilimab injection) was approved by the NMPA for the sixth indication in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.\u003c\/p\u003e","brand":"Innovent Bio, China","offers":[{"title":"Default Title","offer_id":44797954097195,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0711.jpg?v=1787022217"},{"product_id":"sunvozertinib","title":"Sunvozertinib","description":"\u003cp\u003eSunvozertinib (DZD9008) is an oral, potent, irreversible, and selective EGFR TKI targeting EGFR exon20ins as well as \u003cem\u003eEGFR\u003c\/em\u003e sensitizing, T790M, and uncommon mutations with weak activity against wild-type EGFR. \u003c\/p\u003e\u003cp\u003eSunvozertinib is being developed by Dizal Pharmaceuticals, a joint venture between AstraZeneca and the Chinese Future Industry Investment Fund.\u003c\/p\u003e\u003cul\u003e\u003cli\u003eSunvozertinib sold under the brand name 舒沃哲® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eIn August 2023, China’s National Medical Products Administration approved sunvozertinib for the treatment of adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy, based on data from the phase 2 WU-KONG6 trial (NCT05712902).\u003c\/p\u003e","brand":"Dizal Pharma, China","offers":[{"title":"Default Title","offer_id":44797956161579,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-156.jpg?v=1787022252"},{"product_id":"vebreltinib-bozitinib","title":"Vebreltinib (Bozitinib)","description":"\u003ch2\u003eAbout Vebreltinib\u003c\/h2\u003e\u003cp\u003eVebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer . Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.\u003c\/p\u003e\u003cul\u003e\u003cli\u003eVebreltinib sold as brand name 万比锐® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eChina’s National Medical Products Administration (NMPA) has granted conditional marketing approval to vebreltinib (APL-101; PBL-1001) for the treatment of patients with non–small cell lung cancer (NSCLC) harboring \u003cem\u003eMET\u003c\/em\u003e exon 14 skipping mutations.\u003c\/p\u003e\u003cp\u003eChina’s National Medical Products Administration (NMPA) has approved vebreltinib (APL-101; PLB-1001) for the treatment of patients with \u003cem\u003eIDH\u003c\/em\u003e-mutant, World Health Organization grade 4 astrocytoma or glioblastoma who harbor PTPRZ1-MET (ZM) fusions, have a history of low-grade disease, and have progressed on prior treatments.\u003c\/p\u003e","brand":"Avistone Biotechnology, China","offers":[{"title":"Default Title","offer_id":44797956194347,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1557.jpg?v=1787022254"},{"product_id":"ensacove-ensartinib","title":"Ensacove (Ensartinib)","description":"\u003ch2\u003eAbout Ensartinib\u003c\/h2\u003e\u003cp\u003eEnsartinib is a novel, aminopyridazine-based small molecule that potently inhibits ALK. Ensartinib is 10-fold more potent than crizotinib at inhibiting the growth of ALK-positive lung cancer cell lines.Additionally, ensartinib potently inhibited ALK fusions engineered to have point mutations, L1196M and C1156Y, that are associated with crizotinib resistance. Ensartinib also demonstrated potent antitumor activity in H3122 lung cancer xenografts that harbored the \u003cem\u003eEML4-ALK\u003c\/em\u003e E13;A20 fusion, with favorable pharmacokinetic (PK) and safety profiles.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eEnsartinib sold under the brand name Ensacove® in USA.\u003c\/li\u003e\n\u003cli\u003eEnsartinib sold under the brand name 贝美纳® in china.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp class=\"content-title text-center\"\u003e《\u003ca href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ensartinib-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer\" target=\"_blank\" rel=\"noopener\"\u003eFDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer\u003c\/a\u003e》\u003c\/p\u003e\u003ch3\u003eDosage and administration\u003c\/h3\u003e\u003cp\u003eThe recommended dose is 225 mg once daily, taken orally at the same time each day, on an empty stomach or with food.\u003c\/p\u003e\u003cp\u003eIf a dose of Ensartinib is missed and the interval between doses is more than 12 hours, the patient should take the missed dose.\u003c\/p\u003e\u003cp\u003eIf vomiting occurs during treatment, the patient should not take additional doses, but should continue to take the next scheduled dose.\u003c\/p\u003e","brand":"Betta Pharma, China","offers":[{"title":"Default Title","offer_id":44797956227115,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1917.jpg?v=1787022255"},{"product_id":"dupert-fulzerasib","title":"Dupert (Fulzerasib)","description":"\u003ch2\u003eAbout Fulzerasib\u003c\/h2\u003e\u003cp\u003eFulzerasib is a novel, orally active, potent KRAS G12C inhibitor designed to effectively target the GTP\/GDP exchange, an essential step in pathway activation, by modifying the cysteine residue of KRAS G12C protein covalently and irreversibly. Preclinical cysteine selectivity studies demonstrated high selectivity of fulzerasib towards G12C. Subsequently, fulzerasib effectively inhibits the downstream signal pathway to induce tumor cells' apoptosis and cell cycle arrest.\u003c\/p\u003e\u003cul\u003e\u003cli\u003eFulzerasib sold under the brand name 达伯特® (Dupert) in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eRAS protein family can be divided into KRAS, HRAS and NRAS categories. KRAS mutation are detected in nearly 90% of pancreatic cancer, 30-40% of colon cancer, and 15-20% lung cancer patients. The occurrence of KRAS G12C mutation subset is more frequently observed than those with ALK, ROS1, RET and NTRK 1\/2\/3 mutations combined.\u003c\/p\u003e\u003ch3\u003eRecommended dose\u003c\/h3\u003e\u003cp\u003eThe recommended dose of Fulzerasib is 600 mg orally twice a day (approximately 12 hours apart), taken on an empty stomach or after meals, and continued until disease progression or unacceptable toxicity occurs.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eSwallow the tablets whole. Do not chew, crush or split the tablets.\u003c\/li\u003e\n\u003cli\u003eIt is recommended to take this product at the same time every day.\u003c\/li\u003e\n\u003cli\u003eIf you miss a dose during medication, if it is more than 4 hours from the expected dose time, do not make up for it and resume medication at the next scheduled time.\u003c\/li\u003e\n\u003cli\u003eIf vomiting occurs after taking Fulzerasib , do not take another dose.\u003c\/li\u003e\n\u003cli\u003eResume medication at the next scheduled time.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Innovent Biopharmaceutical, China","offers":[{"title":"Default Title","offer_id":44797956259883,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-214.png?v=1787022256"},{"product_id":"anike-penpulimab","title":"Anike (Penpulimab)","description":"\u003ch2\u003eAbout \u003cspan data-huuid=\"5813577302449632437\"\u003ePenpulimab\u003c\/span\u003e\n\u003c\/h2\u003e\u003cp\u003e\u003cspan data-huuid=\"5813577302449632437\"\u003ePenpulimab is an IgG1 monoclonal antibody that's designed to eliminate Fcγ receptor binding and Fc-mediated effector functions. \u003c\/span\u003e\u003cspan data-huuid=\"5813577302449633568\"\u003eThis is intended to reduce immune-related adverse events (irAEs) while maintaining efficacy.\u003c\/span\u003e\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003ePenpulimab \u003c\/span\u003e sold under the brand name 安尼可® (Anike) in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eIn August 2021, penpulimab received its first approval in China for the treatment of adult patients with relapsed or refractory classic Hodgkin's lymphoma who have undergone at least second-line chemotherapy. Penpulimab is under regulatory review for nasopharyngeal cancer and NSCLC in China. Clinical studies of penpulimab are underway for various cancers in China and Australia. This article summarizes the milestones in the development of penpulimab leading to this first approval for relapsed or refractory classic Hodgkin's lymphoma.\u003c\/p\u003e","brand":"Chia Tai Tianqing, China","offers":[{"title":"Default Title","offer_id":44797956325419,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-236.jpg?v=1787022257"}],"url":"https:\/\/xomeds.com\/collections\/lung-cancer.oembed?page=3","provider":"XOMEDS","version":"1.0","type":"link"}